{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:49:43Z","timestamp":1780066183385,"version":"3.54.0"},"reference-count":103,"publisher":"Informa UK Limited","issue":"15","funder":[{"DOI":"10.13039\/100011722","name":"funding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2022,10,13]]},"DOI":"10.1080\/14656566.2022.2130246","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T08:51:30Z","timestamp":1664355090000},"page":"1701-1710","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy"],"prefix":"10.1080","volume":"23","author":[{"given":"Kelsie D.","family":"Kracht","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Eichorn","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3727-952X","authenticated-orcid":false,"given":"Daniel J.","family":"Berlau","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"cit0001","unstructured":"Venugopal V, Pavlakis S. Duchenne muscular dystrophy. 2022."},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.689533"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07815-7"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-021-01933-4"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2013.08.023"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.043638"},{"issue":"1","key":"cit0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/biomedicines10010009","volume":"10","author":"Tulangekar A","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"cit0008","first-page":"184","volume":"31","author":"Klingler W","year":"2012","journal-title":"Acta Myol"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.rehab.2013.06.002"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012910"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01862-w"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03862-2"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04587-3"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-1062-0"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13934"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000669"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01758-9"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170280"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32160-8"},{"key":"cit0021","doi-asserted-by":"crossref","unstructured":"Bushby K, Finkel R, Birnkrant DJ, et al. Review diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. 2010;77.","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"cit0022","doi-asserted-by":"crossref","unstructured":"Gloss D, Moxley Iii RT, Ashwal S, et al. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy. 2016.","DOI":"10.1212\/WNL.0000000000002337"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200556"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.2146\/news170020"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.44786"},{"key":"cit0026","volume-title":"Prednisone [package insert]","year":"2012"},{"key":"cit0027","volume-title":"Emflaza [package insert]","year":"2017"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200110000-00006"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003217"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26736"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.06.124"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.4315"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27428"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2022.04.004"},{"key":"cit0035","first-page":"2","author":"Heier CR","year":"2019","journal-title":"Life Sci Alliance"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44178"},{"key":"cit0037","unstructured":"Vamorolone IP. Filing for FDA approval for DMD expected by June [Internet]. 2022 [cited 2022 Jul 6]. Available from: https:\/\/musculardystrophynews.com\/news\/santhera-reveragen-start-fda-application-seeking-approval-vamorolone-dmd\/."},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.02.001"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210689"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.207449"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50978"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-0156-6"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22758"},{"key":"cit0044","volume-title":"Exondys 51 [package insert]","year":"2016"},{"key":"cit0045","unstructured":"Silverman E. Sarepta to charge $300K for Duchenne drug. \u201cWe tried to be reasonable,\u201d CEO says. 2016 [cited 2022 Jun 30]; Available from: https:\/\/www.statnews.com\/pharmalot\/2016\/09\/19\/sarepta-duchenne-drug-prices\/."},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015858"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23982"},{"key":"cit0048","unstructured":"Califf RM. Center for drug evaluation and research. 2016 [cited 2022 Jun 21]; Available from: https:\/\/www.accessdata.fda.gov\/drug satfda_docs\/nda\/2016\/206488_summaryreview_Redacted.pdf."},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210643"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555"},{"key":"cit0051","volume-title":"Vyondys 53 [package insert]","year":"2019"},{"key":"cit0052","unstructured":"Vyondys FM. 53 available to Duchenne patients in the US. 2019 [cited 2022 Jun 29]; Available from: https:\/\/musculardystrophynews.com\/news\/vyondys-53-available-duchenne-patients-in-the-us\/."},{"key":"cit0053","unstructured":"Vinluan F, Flags FDA. Risk of infection, kidney damage for Sarepta Duchenne drugs. 2020 [cited 2022 Jun 29]; Available from: https:\/\/xconomy.com\/boston\/2020\/01\/22\/fda-flags-risk-of-infection-kidney-damage-for-sarepta-duchenne-drugs\/."},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009233"},{"key":"cit0055","volume-title":"Viltepso [package insert]","year":"2020"},{"key":"cit0056","unstructured":"Fidler B. FDA gives speedy approval to another Duchenne drug. 2020 [cited 2022 Jun 30]; Available from: https:\/\/www.biopharmadive.com\/news\/viltolarsen-duchenne-fda-approval-ns-pharma\/583410\/."},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51235"},{"key":"cit0058","volume-title":"Amondys 45 [package insert]","year":"2021"},{"key":"cit0059","unstructured":"Terry M. FDA Approves Third Sarepta treatment for Duchenne muscular dystrophy. 2021 [cited 2022 Jun 30]; Available from: https:\/\/www.biospace.com\/article\/fda-greenlights-sarepta-s-amondys-45-for-duchenne-muscular-dystrophy\/."},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0061","unstructured":"FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation [Internet]. 2020 [cited 2022 Jul 5]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation."},{"key":"cit0062","unstructured":"FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation [Internet]. 2019 [cited 2022 Jul 5]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation."},{"key":"cit0063","unstructured":"FDA approves targeted treatment for rare Duchenne muscular dystrophy mutation [Internet]. 2021 [cited 2022 Jul 5]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0."},{"key":"cit0064","unstructured":"Agboola F. The effectiveness and value of deflazacort and exon-skipping [Internet]. 2020. Available from: https:\/\/icer-review.org\/pro-"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180357"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1007\/s10974-019-09535-9"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw236"},{"key":"cit0068","unstructured":"Wexler M. SRP-5051. 2022 [cited 2022 Jun 22]; Available from: https:\/\/musculardystrophynews.com\/srp-5051\/."},{"key":"cit0069","unstructured":"Sarepta therapeutics provides update on SRP-5051 for the treatment of Duchenne muscular dystrophy [Internet]. 2022 [cited 2022 Jul 6]. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-provides-update-srp-5051-treatment-duchenne."},{"key":"cit0070","unstructured":"Wexler M. Exon 45 skipping therapy for DMD shows safety in small trial. 2021 [cited 2022 Jul 4]; Available from: https:\/\/musculardystrophynews.com\/news\/ds-5141-shows-promise-in-small-dmd-clinical-trial\/."},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy171"},{"key":"cit0072","unstructured":"Wexler M. Wave life sciences discontinues development of suvodirsen for DMD. 2019 Dec 17 [cited 2022 Jun 22]; Available from: https:\/\/musculardystrophynews.com\/news\/wave-life-sciences-discontinues-suvodirsen-development-for-dmd\/."},{"key":"cit0073","unstructured":"Arif M. Results from Italfarmaco\u2019s EPIDYS trial. 2022 [cited 2022 Jul 4]; Available from: https:\/\/www.actionduchenne.org\/results-from-italfarmacos-epidys-trial\/?utm_source=rss&utm_medium=rss&utm_campaign=results-from-italfarmacos-epidys-trial."},{"key":"cit0074","unstructured":"Shawi F, Perras C, Severn M, et al. Emerging drugs for Duchenne muscular dystrophy. 2016."},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.07.002"},{"key":"cit0076","unstructured":"Mccormack K. HOPE for patients with a muscle destroying disease. 2022 [cited 2022 Jul 4]; Available from: https:\/\/blog.cirm.ca.gov\/tag\/cap-1002\/."},{"key":"cit0077","unstructured":"Mcdonald CM, Marb\u00e1n E, Hendrix S, et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [Internet]. 2022. Available from: www.thelancet.com."},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.09.003"},{"key":"cit0079","unstructured":"Tamoxifen IP. Fails to show efficacy in Duchenne patients in Phase 3 trial [Internet]. 2021 [cited 2022 Jul 6]. Available from: https:\/\/musculardystrophynews.com\/news\/tamoxifen-fails-efficacy-goal-phase-3-trial-duchenne-muscular-dystrophy\/."},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-022-00214-x"},{"key":"cit0081","unstructured":"Wexler M. FDA Places Pamrevlumab for DMD on fast track. 2021 [cited 2022 Jul 6]; Available from: https:\/\/musculardystrophynews.com\/news\/pamrevlumab-fda-fast-track-designation-duchenne-muscular-dystrophy\/."},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210678"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.007"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.3390\/genes13020257"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1725469"},{"key":"cit0086","unstructured":"Wexler M. Phase 3 trial of pfizer\u2019s gene therapy expected to open in US in June. 2022 May 3 [cited 2022 Jun 22]; Available from: https:\/\/musculardystrophynews.com\/2022\/05\/03\/phase-3-trial-of-pfizers-gene-therapy-expected-to-open-in-us-in-june\/."},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14670"},{"issue":"12","key":"cit0088","author":"Garegnani L","year":"2021","journal-title":"Cochrane database of systematic reviews"},{"key":"cit0089","first-page":"1475","volume":"11","author":"LoMauro A","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1732350"},{"key":"cit0091","unstructured":"Stewart J. FDA Rejects New Drug application for translarna to treat DMD [Internet]. 2017 [cited 2022 Jul 6]. Available from: https:\/\/musculardystrophynews.com\/news\/dmd-fda-rejects-new-drug-application-translarna\/."},{"key":"cit0092","unstructured":"Keown A. PTC ready to take another shot at FDA approval of DMD drug, translarna. 2022."},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.09.003"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01197-9"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101059"},{"key":"cit0096","first-page":"6","author":"Hayashiji N","year":"2015","journal-title":"Nat Commun"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00566"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104999"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.03.031"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12735"},{"key":"cit0101","unstructured":"Idrus A. Summit dumps ezutromid after phase 2 Duchenne fail [Internet]. 2018 [cited 2022 Jul 6]. Available from: https:\/\/www.fiercebiotech.com\/summit-dumps-ezutromid-after-phase-2-duchenne-fail."},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-00687-z"},{"key":"cit0103","unstructured":"Institute for clinical and economic review (ICER). Deflazacort, eteplirsen, and golodirsen for Duchenne muscular dystrophy: effectiveness and value final evidence report [Internet]. Available from: https:\/\/icer-review.org\/programs\/new-england-cepac\/."}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2022.2130246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:57:34Z","timestamp":1667408254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2022.2130246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":103,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,10,13]]}},"alternative-id":["10.1080\/14656566.2022.2130246"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2022.2130246","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}